Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]
In development [GID-TA10786] Expected publication date: TBC
Search results
537 results
-
-
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
In development [GID-TAG423] Expected publication date: TBC
-
Nivolumab in combination for untreated advanced unresectable recurrent or metastatic oesophageal squamous cell carcinoma [ID2712]
In development [GID-TA10572] Expected publication date: 23 November 2022
-
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
In development [GID-TA10377] Expected publication date: TBC
-
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]
In development [GID-HST10052] Expected publication date: TBC
-
Voclosporin with immunosuppressives for treating lupus nephritis [ID3962]
In development [GID-TA10878] Expected publication date: 25 January 2023
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: 10 August 2022
-
Autologous auto-CD19-transduced CD3+ cells for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia in adults ID1494
In development [GID-TA10424] Expected publication date: 14 December 2022
-
Head injury: assessment and early management
In development [GID-NG10164] Expected publication date: 23 February 2023
-
Memokath-051 stent for ureteric obstruction
In development [GID-MT569] Expected publication date: 07 December 2022
-
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
In development [GID-TA10539] Expected publication date: TBC
-
Sebelipase alfa for treating Wolman disease [ID3995]
In development [GID-HST10047] Expected publication date: TBC
-
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping [ID1387]
In development [GID-TA10846] Expected publication date: TBC
-
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
In development [GID-HST10037] Expected publication date: TBC
-
Amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy [ID3836]
In development [GID-TA10729] Expected publication date: 12 October 2022
-
Alcohol-use disorders: prevention (update)
In development [GID-NG10299] Expected publication date: TBC
-
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
In development [GID-TA10886] Expected publication date: TBC
-
Social, emotional and mental wellbeing in primary and secondary education
In development [GID-NG10125] Expected publication date: 06 July 2022
-
Empagliflozin for treating chronic heart failure with preserved ejection fraction [ID3945]
In development [GID-TA10946] Expected publication date: TBC
-
Eptinezumab for preventing migraine [ID3803]
In development [GID-TA10677] Expected publication date: TBC
-
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]
In development [GID-TA10635] Expected publication date: TBC
-
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455
In development [GID-TA10356] Expected publication date: TBC
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604
In development [GID-TA10518] Expected publication date: TBC
-
Constipation (opioid induced) - lubiprostone [ID646]
In development [GID-TAG367] Expected publication date: TBC
-
Systemic lupus erythematosus - prasterone [ID392]
In development [GID-TAG373] Expected publication date: TBC
-
Stroke rehabilitation in adults
In development [GID-NG10175] Expected publication date: 18 October 2023
-
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
In development [GID-TA10467] Expected publication date: TBC
-
Lasmiditan for treating acute migraine [ID3759]
In development [GID-TA10807] Expected publication date: 29 March 2023
-
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
In development [GID-TA10598] Expected publication date: TBC
-
Glioblastoma - bevacizumab [ID80]
In development [GID-TAG413] Expected publication date: TBC
-
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]
In development [GID-TA10579] Expected publication date: 19 October 2022
-
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178
In development [GID-TA10199] Expected publication date: TBC
-
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
In development [GID-TA10606] Expected publication date: 08 March 2023
-
Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]
In development [GID-TAG436] Expected publication date: TBC
-
Weight Management: preventing, assessing and managing overweight and obesity (update)
In development [GID-NG10182] Expected publication date: 22 June 2023
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]
In development [GID-TA10544] Expected publication date: TBC
-
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer ID1404
In development [GID-TA10327] Expected publication date: TBC
-
Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]
In development [GID-TA10341] Expected publication date: TBC
-
Spasticity (after stroke) - botulinum toxin type A [ID768]
In development [GID-TAG499] Expected publication date: TBC
-
Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)
In development [GID-TA10337] Expected publication date: 19 February 2020
-
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997
In development [GID-TA10382] Expected publication date: TBC
-
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
In development [GID-HST10004] Expected publication date: TBC
-
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]
In development [GID-TAG278] Expected publication date: TBC
-
Belimumab for treating lupus nephritis [ID2722]
In development [GID-TA10853] Expected publication date: TBC
-
Pembrolizumab with epacadostat for untreated malignant melanoma ID1423
In development [GID-TA10330] Expected publication date: TBC
-
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228
In development [GID-TA10203] Expected publication date: TBC
-
Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]
In development [GID-TA10149] Expected publication date: TBC
-
Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]
In development [GID-TAG410] Expected publication date: TBC